Tuesday, 17 July 2018

Call for Abstract: Drug Discovery and Development

Drug discovery is a process where the cure for the disease is found. This is a multistep process which involves a great amount of investment in terms of time and finance.
Cancer is believed not be cured any drugs. However, there are many instances where people have come out of this disease successfully, thanks to the researchers who have developed some efficient molecules which can suppress and kill the tumor cells.
As a first step, the cause of the disease is identified. Here it might be a molecule or an Organism. Once the cause is identified, a hypothesis for the target molecules are drawn and certain molecule groups are chosen to encounter the target molecule/Organism. In the modern method, these molecules are chosen by algorithms and often selected from the databases based upon their structures and composition. Later these are subjected to the target molecule in silico models. Many of the molecules lose the race here and few make it to the next level of testing where the selected models are subjected to animal models. Once these molecules are proven to be safe and efficient in the animal models, they are approved to test on the human. After rigor testing and monitoring, a suitable molecule with all ideal characteristics is approved by the governing body and released into the market.
  • Innovative Drug Discovery and Nanotechnology
  • Computer-Aided Drug Design Methods (CADD)
  • Combinatorial Chemistry in Drug Discovery
  • Smart Drug Delivery Systems
  • Structural Biology in Drug Development
Abstract submission portal for the "24th Global Meet on Cancer Research and Oncology" is open now. To submit your abstract for presentation at this event, visit- Cancer Conferences Abstract Submission

Relevant Conferences:
Global Summit on Oncology & Cancer March 12-14, 2018 Singapore; 2nd International Conference on Cancer Genetics and Epigenetics, May 24-25, 2018 Tokyo, Japan; 22nd Global Annual Oncologists Meeting May 24-25, 2018 Osaka, Japan; World Haematology and Medical Oncology Conference May 28-29, 2018 Osaka, Japan; Global Meeting on Oncology and Radiology June 1-2, 2018 Osaka, Japan; Cancer Genomics Conference: New Era for Cancer Prevention June 25-26, 2018 Dubai, UAE; World Cancer Summit 2018 July 02-03, 2018 Bangkok, Thailand; International Conference on Biomarkers and Cancer Targets July 16-17, 2018 Dubai, UAE; 4th Annual Conference on Preventive Oncology July 18-19, 2018 Atlanta, Georgia, USA; 4th Annual Conference on Gynaecologic Oncology and Reproductive Disorders July 18-19, 2018 Atlanta, Georgia, USA; 29th Euro-Global Summit on Cancer Therapy & Radiation Oncology July 23-25, 2018 Rome, Italy; Experts Meet On Cancer Therapy 2018 July 23-24, 2018 Melbourne, Australia.

Tuesday, 10 July 2018

Call for Abstracts: Cancer Genomics and Epigenetics

This is a branch of genomics which deals with the genomic content of the host. How the genomes in the host affect the carcinogenesis and what will happen if simple changes occur in these, what can be done to prevent this from happening or to cure the same.
The entire DNA contained in your cells makes up your genome. In many cells, the genome is bundled into two arrangements of chromosomes: one set each from the parents. These chromosomes are made out of six billion individual DNA letters. In the English letter set, there are 26 letters: A through Z. In the letters in order of our qualities, there are four letters: A, C, G and T. Much the same as the letters in a book make words to recount a story, so do the letters in our genomes. Genomics is the investigation of the grouping of these letters in your DNA and how each series of letters passes data to enable every cell in your body to work legitimately.
In tumor cells, little changes in the hereditary letters can change what a genomic word or sentence implies. A changed letter can make the cell make a protein that doesn't enable the cell to fill in as it should. These proteins can influence cells to develop rapidly and cause damage to the neighboring cells. By concentrating on the cancer genome, researchers can find what letter changes are making a cell turn into a disease. The genome of a tumor cell can likewise be utilized to reveal to one sort of tumor from another. Sometimes, considering the genome in a disease can help distinguish a subtype of growth inside that compose, for example, HER2+ breast tumor. Understanding the malignancy genome may likewise enable a researcher to choose the best treatment for every patient.
  • Functional Studies of the Cancer Genome and Epigenome
  • The Genetics and Epigenetics of Immuno-Oncology
  • Computational Approaches to Cancer Genetics and Epigenetics
  • The Cancer Epi-Transcriptome
  • Genome-Wide Studies of Epigenetics and Cancer
Relevant Conferences: 
26th Annual Congress on Cancer Science and Targeted Therapies October 29-30, 2018 San Francisco, California, USA; International Conference on Gastrointestinal Cancer and Therapeutics October 29-30, 2018 San Francisco, California, USA; International Conference on Robotic Oncology October 26-27, 2018 Osaka, Japan; 36th World Cancer Conference October 11-13, 2018 Zurich, Switzerland; International Conference on Cancer Science & Robotics August 1-2, 2018 Melbourne, Australia; 5th World Congress on Epigenetics and Chromosome October 22-24, 2018 Turkey; Euro Breast Cancer Summit October 18-19, 2018 | Amsterdam, Netherlands; Annual Congress on Cancer and Stem Cell Research October 17-18, 2018 New York, USA; 22nd World Conference on Liquid Biopsy & Biomarkers October 15-16, 2018 Toronto, Canada; International Conference on Molecular Markers and Cancer Therapeutics October 8-9, 2018 Dubai, UAE; International Conference on Cancer DiagnosisTreatment August 2-3 2018 Oslo, Norway; 12th World Congress on Biomarkers & Clinical Research October 03-04, 2018 Los Angeles, California, USA; ESMO Asia CongressRCE-ESMO-ESO Training Course for Rare Cancer Patient Advocates. ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers. ESMO Congress.

Friday, 6 July 2018

Call for Abstracts: Biomarkers in Cancer Research

Biomarkers are the Biological subjects which are used to detect the presence of tumor in the early stages.
Biomarkers give a capable and dynamic way to deal with understanding the range of tumors with applications in observational and logical the study of disease transmission, randomized clinical trials, screening, analysis, and detection. Characterized as changes in the constituents of tissues or body liquids, these markers offer a method for homogeneous arrangement of a sickness and hazard factor, and they can expand one's fundamental data about the hidden pathogenesis of cancer.
The objectives in tumor explore incorporate discovering biomarkers that can be utilized for the early location of carcinogenesis, outline singular treatments, and to recognize fundamental procedures associated with the malady. Since such a significant number of heap forms are associated with the unhealthy states, the objective is like 'finding a needle in a pile'. In any case, the improvement of many - Omics advancements, for example, genomics and proteomics, has enabled us to screen countless cell pathways at the same time. This has empowered the distinguishing proof of biomarkers and flagging atoms related to cell development, cell passing, and cell digestion. These are additionally encouraging in checking the practical unsettling influence, sub-atomic and cell damage and reaction.
  • Molecular Biomarkers
  • Toxicity Prediction
  • Clinical Application of Biomarkers
  • Biomarkers in Radiology
  •  Biomarker Research
"24th Global Meet on Cancer Research and Oncology" is now accepting abstract under the category "Biomarkers in Cancer Research".
To submit your abstracts, visit- Cancer Conferences Abstract Submission

Cancer Conferences | Biomarkers Conferences | Oncology Conferences | Events |
 Canada | Toronto

Wednesday, 4 July 2018

Call for Abstracts: Cancer Pharmacology

Pharmacology is a branch of Medicine that deals with the use of the drugs in their formulations, intake and their mechanism inside the host.
Cancer Pharmacology is a branch of Pharmacology which deals with the drug taken to suppress the growth of cancer. This branch usually deals with the interaction of the drug molecules with the cancer cells, how they behave with the normal host cells and tumor cells, their ability to differentiate both and their mechanism of killing the cancer cells.
Drug Discovery and Development in the field of Oncology is solely depending on Cancer Pharmacology. Here the drug molecules developed will be first tried in the In-silico models later the succeeded ones will be given to the animal models. Approved drugs will be used for the use of humans.
  • Pharmacokinetics and Pharmacodynamics
  • Biochemical Pharmacology
  • Cancer Drug Targets
  • Clinical Pharmacology
We are now accepting the abstracts for presentation at the "24th Global Meet on Cancer Research and Oncology"- Toronto. To submit your abstract for the conference, please visit: Abstract Submission- Cancer Pharmacology Conferences

Relevant Conferences: 

Global Summit on Oncology & Cancer  Singapore; 2nd International Conference on Cancer Genetics and Epigenetics; 22nd Global Annual Oncologists Meeting ; World Haematology and Medical Oncology Conference ; Global Meeting on Oncology and Radiology June 1-2, 2018 Osaka, Japan; Cancer Genomics Conference: New Era for Cancer Prevention June 25-26, 2018 Dubai, UAE; World Cancer Summit 2018 July 02-03, 2018 Bangkok, Thailand; International Conference on Biomarkers and Cancer Targets July 16-17, 2018 Dubai, UAE; 4th Annual Conference on Preventive Oncology July 18-19, 2018 Atlanta, Georgia, USA; 4th Annual Conference on Gynaecologic Oncology and Reproductive Disorders July 18-19, 2018 Atlanta, Georgia, USA; 29th Euro-Global Summit on Cancer Therapy & Radiation Oncology July 23-25, 2018 Rome, Italy; Experts Meet On Cancer Therapy 2018 July 23-24, 2018 Melbourne, Australia.

Wednesday, 27 June 2018

Call for Abstracts - Cancer Nursing

Oncology medical nurses work in a multi-disciplinary group, in an assortment of settings, from the inpatient ward to deep down marrow transplant unit, through to the group. Oncology nurses regularly fill in as your first line of correspondence and help organize the numerous parts of care all through cancer treatment. They may play out various obligations.
An Oncology Nurse gives care to malignancy patients and those in danger of getting the infection. Oncology medical caretakers must oversee both the side effects of a patient's ailment and the reactions of different tumor medications. They screen physical conditions, endorse medicine, and regulate chemotherapy and different medications. Oncology medical attendants witness much enduring; however, this pressure is balanced by the long haul connections they regularly create with patients and their families.
  • Nurse Practitioner Education
  • Evidence-Based Practice in Nursing
  • Advances in Online Nursing Classes
  • Supportive Care Services
24th Global Meet on Cancer Research and oncology is now accepting abstracts under the category "Cancer Nursing". To submit your abstracts under this category, visit: Abstract Submission- Cancer Conferences


Tuesday, 26 June 2018

Report: New approach to immunotherapy leads to complete response in breast cancer patient unresponsive to other treatments

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments. This patient received the treatment in a clinical trial led by Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch at NCI’s Center for Cancer Research (CCR), and the findings were published June 4, 2018 in Nature Medicine. NCI is part of the National Institutes of Health. 
“We’ve developed a high-throughput method to identify mutations present in cancer that are recognized by the immune system,” Dr. Rosenberg said. “This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer.”
The new immunotherapy approach is a modified form of adoptive cell transfer (ACT). ACT has been effective in treating melanoma, which has high levels of somatic, or acquired, mutations. However, it has been less effective with some common epithelial cancers, or cancers that start in the lining of organs, that have lower levels of mutations, such as stomach, esophageal, ovarian, and breast cancers.
In an ongoing phase 2 clinical trial, the investigators are developing a form of ACT that uses tumor-infiltrating lymphocytes (TILs) that specifically target tumor cell mutations to see if they can shrink tumors in patients with these common epithelial cancers. As with other forms of ACT, the selected TILs are grown to large numbers in the laboratory and are then infused back into the patient (who has in the meantime undergone treatment to deplete remaining lymphocytes) to create a stronger immune response against the tumor.
A patient with metastatic breast cancer came to the trial after receiving multiple treatments, including several chemotherapy and hormonal treatments, that had not stopped her cancer from progressing. To treat her, the researchers sequenced DNA and RNA from one of her tumors, as well as normal tissue to see which mutations were unique to her cancer, and identified 62 different mutations in her tumor cells. 
The researchers then tested different TILs from the patient to find those that recognized one or more of these mutated proteins. TILs recognized four of the mutant proteins, and the TILs then were expanded and infused back into the patient. She was also given the checkpoint inhibitor pembrolizumab to prevent the possible inactivation of the infused T cells by factors in the tumor microenvironment. After the treatment, all of this patient’s cancer disappeared and has not returned more than 22 months later.   
“This is an illustrative case report that highlights, once again, the power of immunotherapy,” said Tom Misteli, Ph.D., director of CCR at NCI. “If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers.” 
Investigators have seen similar results using mutation-targeted TIL treatment for patients in the same trial with other epithelial cancers, including liver cancer and colorectal cancer. Dr. Rosenberg explained that results like this in patients with solid epithelial tumors are important because ACT has not been as successful with these kinds of cancers as with other types that have more mutations. 
He said the “big picture” here is this kind of treatment is not cancer-type specific. “All cancers have mutations, and that’s what we’re attacking with this immunotherapy,” he said. “It is ironic that the very mutations that cause the cancer may prove to be the best targets to treat the cancer.” 
The research team includes Nikolaos Zacharakis, Ph.D.; Steven A. Feldman, Ph.D.; and Stephanie L. Goff, M.D. 
Source: https://www.nih.gov/

Thursday, 21 June 2018

Report: Number of elderly people with cancer to soar by 80% over next two decades

The number of elderly people being diagnosed with cancer is set to rise by 80% over the next two decades, experts have warned.

About 130,000 people over the age of 75 currently get some form of the disease in the UK each year, but Cancer Research UK has predicted that it could soar to 234,000 by 2035 as a result of an aging population.

With a significant gap in survival rates between Britain and the world's best-performing countries when it comes to older cancer patients, the charity has called on the NHS to do more to ensure it is prepared for the major increase.

Head information nurse Martin Ledwick said: "When elderly people have a lot of health problems and are taking a range of different medications, it can affect what treatment they are able to receive.

"Some older people with cancer might not be fit enough to have surgery and go through lengthy periods of chemotherapy and radiotherapy, but as no two patients are the same, there will be others who are.

"That's why it's so important staff are well trained and resourced so they can assess older people properly and ensure they receive the right treatment, care and support specific to their individual needs."

Women who get breast cancer above the age 75 are far more likely to survive for longer in Europe than they are in the UK and Ireland, and survival rates for bowel cancer in the same age group are 15% lower here than in Canada.

The report suggested the rates were notably lower among older patients in the UK because they were more likely to be diagnosed with cancer at a more advanced stage, making it harder to treat.

Between 2006 and 2015, 41% of all cancers in those aged 80 to 84 were diagnosed in an emergency in England, compared with 14% of cancers in those aged between 50 and 59.

Rose Gray, Cancer Research UK's policy manager, added: "If we do nothing, the disparity in care between older and younger cancer patients will only grow.

"It's vital to address this if we want to realize our ambition of ensuring world-class treatment for everyone in the UK who is affected by cancer."

Source: http://bit.ly/2McysE5